To make a list of the Top 10 Global Pharma Companies for the next decade, it is necessary to look at sales, but how does a company rank against its competitors? We use the annual report and press releases distributed throughout the year to compile this information. Our results focus on the sales of pharma/biopharmaceutical companies, but may also include animal health, smaller divisions, and more. We have excluded large diagnostic, consumer, and medical device divisions.
Pfizer
With COVID-19 on the rise, it was no surprise that Pfizer is one of the top global pharmaceutical companies in 2021. While the company has lost a bit of momentum recently, it has recently gained some ground. In Q2’2021, its revenue was $19.0 billion, representing an 86% increase over the same period in 2020. Eli Lilly, another global leader, has taken a major step towards establishing itself as a top player in the pharmaceutical industry. Its market cap was $125 billion in 2019 but has risen to $214.9 billion today.
Other pharmaceutical giants are also achieving impressive growth. AbbVie, which joined the top 50 in February, managed a 23% increase in revenue without releasing COVID-19 meds. And despite the acquisition of Allergan, Merck saw its revenue climb to $17.1 billion in 2020, thanks to the success of its drug Keytruda. Meanwhile, Amgen and Novartis only had modest increases, while Bristol-Myers-Squibb were able to boost their revenue by 4% respectively.
Roche
In the pharmaceutical industry, a brand’s reputation is critical to its success. Brands with high recognition can be a powerful competitive advantage. Several recent global events have proven that brands that are popular among consumers can increase their share of market share. The COVID-19 pandemic was a big deal for pharma companies, and it was this pandemic’s impact on the pharmaceutical industry that made the list.
Investing in R&D is another area in which Roche excels. In 2014, the company invested $11.3 billion in research and development, a 9.8% increase from the year before. The company also has 19 compounds undergoing Phase III clinical trials or filing for approval. The company is well-positioned to take advantage of these opportunities. Roche’s latest acquisition is Spark Therapeutics. The company recently acquired this biotech company for $4.8 billion.
In the science world, Roche has risen to the top spot and has surpassed Pfizer to become the largest pharmaceutical company in the world. With more than 90,000 employees and headquarters in Basel, Switzerland, the company is a leader in immunology, oncology, infectious diseases, neuroscience, and ophthalmology. The company’s pharma division grew 16% in 2019, driven by strong uptake of new medicines. Ocrevus, haemlibra, and Tecentriq are among the company’s top-selling medicines.
Abbvie
Among the top 10 pharmaceutical companies in the world, AbbVie has a history of innovation, with more than 48,000 experts around the globe and operations in 70 countries. The company recently announced an acquisition of Allergan, which strengthened its pipeline for new treatments. In 2020, AbbVie increased revenues by 38% and expects that number to grow even more this year.
During Q1 2021, Abbott sold COVID-19 rapid testing platforms and other new products, boosting sales by 35.3 percent. The company’s sales for this period were $1.8 billion for its COVID-19 rapid testing platforms, and $2.27 billion for its NeuroSphere Virtual Clinic, which allows doctors to communicate with patients over the internet. AstraZeneca’s $39 billion acquisition of Alexion helped the company climb the list to No. 5.
Humira, the company’s most popular drug, is nearing its patent expiration date. Humira sales will account for about 45% of the company’s total revenue, but the company hopes that Skyrizi and Rinvoq will fill the void once the Humira patent is expired. The two approved drugs, for rheumatoid arthritis, psoriasis, and rheumatoid arthritis respectively, will generate about $2 billion in 2020.
Johnson & Johnson
In a recent survey of prestigious companies, Johnson & Johson placed among the top twenty global pharmaceutical companies for 2021. The company has consistently placed high on the Fortune 50 All-Stars list, and is now the world’s leading pharmaceutical company for the eighth consecutive year. The pharmaceuticals business is led by immunology, with revenue of USD 16.7 billion in 2017; however, it has been struggling to compete with biosimilars. In addition to its pharmaceutical business, Johnson & Johnson’s consumer health division is facing significant legal challenges related to claims that baby powder causes cancer.
The company’s research is also focused on health equity, with a mission statement that emphasizes advancing public health and the quality of life around the globe. Recently, Johnson & Johjivn has begun work on an investigational vaccine against COVID-19, a serious bacterial infection. The company has also been developing new products for cancer, such as cancer, to fight the disease.
Novartis
The global pharmaceutical industry is expected to grow at a healthy pace. In 2021, Novartis will make 52 billion dollars in pharmaceutical revenue. In contrast, Pfizer will take the number one spot with record COVID-19 vaccine sales. These companies are leading the way in battling the virus. The next few years will see a rise in both the number of illnesses and the cost of medicines. ultra woman vitamins
Pfizer is the former number one. The Swiss company specializes in the research and development of medicines and vaccines. It employs over 88,000 employees and provides healthcare solutions to 150 countries. Pfizer has had to deal with costly patent expirations and is expected to lose money on more expirations in 2019. Its consumer health division has been weak, while its biopharma division offset this by acquiring Upjohn.
AstraZeneca is poised to join the top ten next year after announcing a partnership with the biotechnology company BeiGene. The company’s tislelizumab is currently in head-to-head trials against Sanofi’s docetaxel drug. With this success, it will have a successful expansion strategy that could lead to record revenues in 2023.
Bayer
The late-stage pipeline of Bayer is packed with promising candidates with the potential to become blockbusters. The company focuses on diseases with high unmet medical needs, such as chronic kidney disease associated with type-2 diabetes and heart failure. Additionally, Bayer is working on treatments for the vasomotor symptoms associated with menopause. Currently, Bayer is advancing approximately 50 projects through the clinic. ultra men vitamins
Sanofi is a leading maker of HIV/AIDS, cancer, and diabetes medicines. The company recently saw a resurgence in its business thanks to the approval of two new drugs. Rezurock, for example, is a treatment for chronic graft vs. host disease. It is also a leader in the field of immunology. In 2021, Sanofi’s stock price is expected to grow by around 19 percent, following the spinoff of Upjohn.
Lilly is another biopharmaceutical company in the top 10 list. The company recently announced a $7 billion R&D budget, a 15% increase from the previous year. This R&D budget lands the company at a 25% revenue level. The company’s pipeline is currently focused on two drugs, donanemab for Alzheimer’s disease and tirzepatide for Type 2 diabetes. In October, the company trimmed another drug, zagotenemab for the treatment of obesity.
Merck Merck Sharp & Dohme
The pharmaceutical company, Merck & Co., Inc. (or MSD outside the United States) is an American multinational pharmaceutical company. Founded in 1891, Merck has been one of the most successful companies in the history of the pharmaceutical industry. The company’s products and services have been instrumental in saving millions of lives. Its products range from vaccines to autoimmune disorders, and it generates 46 billion U.S. dollars annually.
In 2020, Novartis is expected to see a steady increase in revenue due to its pipeline of promising drugs and products. With two new molecular entities and 21 approvals in the pipeline in 2021, Novartis is poised for an impressive growth year. Revenues from its products will grow six percent in 2021, and more than 20 assets are expected to be approved by 2026, with over USD 1 billion in sales potential.
The world’s pharmaceutical industry is projected to grow strongly in 2020. The top 15 pharmaceutical companies will account for approximately one-third of the total global market in 2021. Sales of drugs will reach 1.4 trillion US dollars, which is an impressive growth rate. Merck, Sharp & Dohme, Novartis, and Sanofi are among the companies expected to see the most growth.
Bristol Myers Squibb
The New York-based pharmaceutical company produces both biologics and prescription drugs. With a strong pipeline, Bristol-Myers Squibb is well-positioned to benefit from the growing global oncology market. It currently produces cancer drugs such as Orencia and has received over twenty regulatory approvals for new products. In addition, the company has been able to expand its geographic footprint through acquisitions such as Celgene.
Johnson & Johnson is a diversified healthcare company that produces consumer goods and medical devices. Its pharmaceutical division grew 8.4% last year, despite the negative impact of Covid-19, a vaccine against the cytomegalovirus. The company employs nearly 29 million people globally and produces 50% of the world’s insulin. This year, it’s expected to grow by over 10%.
Despite this slowdown, Bristol Myers Squibb remains one of the most profitable global pharma companies. Its recent acquisition of the biotech firm Celgene boosted its revenue by 63%. It is also expected to increase its revenue with sales from its controversial Alzheimer’s disease drug Aduhelm. However, two companies fell out of the top 10.